` BEFORE THE PATENT TRIAL AND APPEAL BOARD
` - - - - - - - - - - - - - - - - -
`
`PFIZER, INC. and SAMSUNG BIOEPIS
`CO., LTD.,
`
` Petitioners, Case No.:
` IPR2017-01488
` IPR2017-01489
` Patent 6,407,213
`-vs.-
`GENENTECH, INC.,
` Patent Owner.
`
`- - - - - - - - - - - - - - - - -
` Case IPR2017-02139 has been joined with this
`proceeding.
` Case IPR2017-02140 has been joined with this
`proceeding.
` Deposition of IAN A. WILSON, D.Phil.
` La Jolla, California
` Saturday, April 21, 2018
` 9:07 a.m.
`Job No.: 185272
`Pages: 1 - 299
`Reported by: Tricia Rosate, RDR, RMR, CRR, CCRR
`CSR No. 10891
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`
`
`1 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`2
`
`Deposition OF IAN A. WILSON, D.Phil, held at:
` Residence Inn by Marriott
` 8901 Gilman Drive
` La Jolla, California 92037
` (858) 587-1770
`
` Pursuant to Notice, before Tricia Rosate, RDR,
`RMR, CRR, CCRR, Certified Shorthand Reporter No.
`10891 in and for the State of California.
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`2 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`3
`
` A P P E A R A N C E S
`ON BEHALF OF THE PETITIONER PFIZER, INC.:
` BENJAMIN LASKY, ESQ.
` KIRKLAND & ELLIS, LLP
` 601 Lexington Avenue
` New York, New York 10022
` (212) 446-6415
` blasky@kirkland.com
` -and-
` SHARICK NAQI, ESQ.
` KIRKLAND & ELLIS, LLP
` 300 North LaSalle
` Chicago, Illinois 60654
` (312) 862-3235
` sharick.naqi@kirkland.com
`
`ON BEHALF OF THE PETITIONER CELLTRION INC.:
` ROBERT V. CERWINSKI, ESQ.
` GOODWIN PROCTER, LLP
` 620 Eighth Avenue
` New York, New York 10018
` (212) 459-7240
` rcerwinski@goodwinlaw.com
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`3 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`4
`
` A P P E A R A N C E S (Continued)
`ON BEHALF OF THE PETITIONER SAMSUNG BIOEPIS:
` AMIT THAKORE, ESQ.
` WHITE & CASE, LLP
` 1221 Avenue of the Americas
` New York, New York 10020-1095
` (212) 819-2692
` athakore@whitecase.com
`
`ON BEHALF OF THE PATENT OWNER GENENTECH, INC.:
` ANDREW J. DANFORD, ESQ.
` WILMER CUTLER PICKERING HALE and DORR, LLP
` 60 State Street
` Boston, Massachusetts 02109
` (617) 526-6806
` andrew.danford@wilmerhale.com
` -and-
` NORA Q.E. PASSAMANECK, ESQ.
` WILMER CUTLER PICKERING HALE and DORR, LLP
` 1225 17th Street
` Suite 2600
` Denver, Colorado 80202
` (720) 274-3152
` nora.passamaneck@wilmerhale.com
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`
`
`4 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`5
`
` A P P E A R A N C E S (Continued)
`ALSO PRESENT:
` SARAH MILLER, The Videographer
` TRACI ROPP, Genentech
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`5 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`6
`
` C O N T E N T S
`EXAMINATION OF IAN A. WILSON, D.Phil. PAGE
`By Mr. Lasky ....................... 8, 146, 280
`By Mr. Cerwinski ....................... 268
`By Mr. Danford ....................... 270
`
` E X H I B I T S
` (Attached to transcript)
`WILSON DEPOSITION EXHIBIT PAGE
`Exhibit 1194 "Humanization of a mouse 187
` anti-human IgE antibody: a
` potential therapeutic for
` IgE-mediated allergies"
`
`Exhibit 1195 "Applications and Engineering 217
` of Monoclonal Antibodies"
`
` P R E V I O U S L Y M A R K E D E X H I B I T S
` Exhibit 1001 Exhibit 1055
` Exhibit 1002 Exhibit 1071
` Exhibit 1003 Exhibit 1125
` Exhibit 1021 Exhibit 1193
` Exhibit 1034 Exhibit 2041
` Exhibit 1052
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`
`
`6 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:02:00
`09:02:00
`09:02:00
`09:05:53
`09:05:55
`09:05:58
`09:06:07
`09:06:20
`09:06:30
`09:07:33
`09:07:36
`09:07:38
`09:07:41
`09:07:45
`09:07:50
`09:07:51
`09:07:53
`09:07:55
`09:07:57
`09:07:59
`09:08:01
`09:08:03
`09:08:07
`09:08:09
`09:08:10
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`7
`
` LA JOLLA, CALIFORNIA; SATURDAY, APRIL 21, 2018
` 9:07 A.M. - 6:15 P.M.
` - - - -
` THE VIDEOGRAPHER: Here begins Tape No. 1 in
`the videotaped deposition of Dr. Ian Wilson in the
`matter of Pfizer vs. Genentech and Celltrion vs.
`Genentech, Case No. IPR2017-01486-01489 [sic] and
`Case No. IPR2017-01373-01374.
` Today's date is April 21, 2018. The time on
`the video monitor is 9:07 a.m.
` The videographer today is Sarah Miller,
`representing Planet Depo.
` This video deposition is taking place at
`8901 Gilman Drive, La Jolla, California.
` Will counsel please voice identify
`themselves and state whom they represent.
` MR. LASKY: My name's Ben Lasky from
`Kirkland & Ellis. I represent Pfizer.
` With me today from Kirkland & Ellis is
`Sharick Naqi.
` MR. CERWINSKI: I'm Robert Cerwinski. I'm
`with Goodwin Procter, LLP, and I represent Celltrion,
`petitioner.
` MR. THAKORE: Amit Thakore from White & Case
`representing petitioner Samsung Bioepis.
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`7 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:08:17
`09:08:17
`09:08:17
`09:08:22
`09:08:24
`09:08:25
`09:08:29
`09:08:31
`09:08:43
`09:08:43
`09:08:43
`09:08:43
`09:08:43
`09:08:44
`09:08:46
`09:08:52
`09:08:53
`09:08:53
`09:08:54
`09:08:55
`09:08:56
`09:08:58
`09:09:00
`09:09:01
`09:09:01
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`8
`
` MR. DANFORD: Andrew Danford from WilmerHale
`representing patent owner, Genentech and the witness,
`and I'm joined today by Nora Passamaneck of
`WilmerHale and Traci Ropp of Genentech.
` THE VIDEOGRAPHER: Okay. The court reporter
`today is Tricia Rosate representing Planet Depo.
` Will the reporter please swear in the
`witness.
` IAN A. WILSON, D.Phil.,
` having been first duly sworn, testified as follows:
` EXAMINATION
`BY MR. LASKY:
` Q Good morning, Dr. Wilson.
` I just need to say something for the record.
`The first case number, 2017-01488, and that's my
`fault, my handwriting. So --
` Good morning.
` A Good morning.
` Q Could you please state your full name for
`the record.
` A Ian Andrew Wilson.
` Q And have you had your deposition taken
`before?
` A Yes.
` Q How many times?
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`8 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:09:03
`09:09:05
`09:09:05
`09:09:07
`09:09:08
`09:09:11
`09:09:14
`09:09:19
`09:09:23
`09:09:24
`09:09:26
`09:09:27
`09:09:30
`09:09:31
`09:09:32
`09:09:34
`09:09:38
`09:09:39
`09:09:40
`09:09:41
`09:09:48
`09:09:48
`09:09:50
`09:09:51
`09:09:53
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`9
`
` A I can't remember how many. About three or
`four.
` Q Okay. And were they all in connection with
`expert witness work?
` A Yes.
` Q Okay. How many times have you previously
`served as an expert witness in a litigation or
`patent office proceeding?
` A Could you explain?
` Q Sure. Well, let's start with a
`district court action.
` Have you ever served as an expert in a court
`action?
` A One. One time.
` Q Okay. And who were you retained by in that
`case?
` A WilmerHale.
` Q Okay. And who was the --
` Well, first of all, was Genentech the party
`that you were representing there?
` A I don't think so.
` Q Okay. Do you know who the party was?
` A I can't remember.
` Q Okay. Was the party the patent owner?
` Well, strike that.
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`9 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:09:55
`09:09:57
`09:10:00
`09:10:04
`09:10:08
`09:10:09
`09:10:10
`09:10:11
`09:10:13
`09:10:23
`09:10:23
`09:10:25
`09:10:26
`09:10:29
`09:10:31
`09:10:31
`09:10:34
`09:10:34
`09:10:41
`09:10:43
`09:10:44
`09:10:47
`09:10:49
`09:10:52
`09:10:55
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`10
`
` Was this a patent case?
` A It's such a long time ago, I can't -- I
`don't actually remember the details of the case. I
`actually destroy the documents, and I destroy it from
`my memory, too. So --
` Q Fair enough.
` Do you know what the issues were that you
`were giving an opinion on in that case?
` A It had to do with epitopes on -- on a
`receptor.
` Q And was it relating to a therapeutic
`product?
` A As far as I -- I recall, yes.
` Q Do you recall what the product was?
` A No.
` Q Okay. And you were deposed in that case?
` A Yes.
` Q Okay. Other than that case, have you ever
`been involved in a case in the district court or in
`any court?
` A No.
` Q All right. Have you ever served as an
`expert witness previously in an action before the
`U.S. Patent and Trademark Office?
` A In what sense? I don't really --
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`10 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:10:57
`09:10:59
`09:11:00
`09:11:02
`09:11:06
`09:11:09
`09:11:10
`09:11:11
`09:11:13
`09:11:15
`09:11:19
`09:11:20
`09:11:24
`09:11:32
`09:11:34
`09:11:35
`09:11:37
`09:11:44
`09:11:45
`09:11:50
`09:11:51
`09:11:53
`09:11:55
`09:11:55
`09:11:58
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`11
`
` You -- I'm not understanding some of the
`questions.
` Q Okay. Sure. So you understand that the
`proceeding that you're here for today is an
`inter partes review in the U.S. Patent and Trademark
`Office?
` Do you understand that?
` A I understand it now.
` Q Oh, okay. Okay. Well, why don't you tell
`me. What other cases have you been involved in as an
`expert witness?
` A They've -- they'e largely been to do -- to
`do with -- cases to do with -- with patents. By and
`large, I think it's been patents.
` I had one other case that had noth- -- that
`was -- that was a separate issue that was just a
`dispute between parties on some scientific grounds.
` Q Okay. Have you ever previously been
`retained by Genentech in a legal matter?
` A Yes.
` Q And -- and what -- what did that involve?
` A That involved -- similar to dealing with
`patents.
` Q And was it relating to the product
`Herceptin?
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`11 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:12:00
`09:12:01
`09:12:02
`09:12:02
`09:12:03
`09:12:04
`09:12:06
`09:12:12
`09:12:15
`09:12:17
`09:12:19
`09:12:20
`09:12:26
`09:12:27
`09:12:28
`09:12:32
`09:12:34
`09:12:37
`09:12:37
`09:12:41
`09:12:43
`09:12:51
`09:12:53
`09:12:55
`09:12:56
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`12
`
` A Other than this case?
` Q Yes.
` A No.
` Q Okay.
` A Not -- not that I remember.
` Q Okay. So the other case that you worked
`with -- worked on with Genentech, what product was
`involved in that case?
` A I can't remember what -- what those were.
` Q Okay. Was -- was that in the U.S. or
`somewhere else?
` A U.S. Or those -- those are Brazilian
`proceedings as well.
` Q Okay. And when was this?
` A That's been ongoing for the last year or so.
` Q Okay. And were you -- have you had a
`deposition taken in that case?
` A No.
` Q Okay. Other than in litigation or in the
`patent office, have you ever been retained by
`Genentech as a consultant?
` A Not to the -- not to my knowledge.
` Q Have you ever received funding from
`Genentech?
` A Funding from -- personally or for my lab?
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`12 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:12:58
`09:13:05
`09:13:06
`09:13:07
`09:13:07
`09:14:05
`09:14:07
`09:14:15
`09:14:24
`09:14:26
`09:14:47
`09:14:49
`09:14:57
`09:14:57
`09:15:00
`09:15:02
`09:15:03
`09:15:04
`09:15:09
`09:15:12
`09:15:13
`09:15:14
`09:15:15
`09:15:17
`09:15:19
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`13
`
` Q For your lab.
` A No.
` Q Okay. And personally?
` A No.
` Q Okay. The declarations --
` I've handed you two documents, Dr. Wilson.
`One is marked Exhibit 2041 in IPR2017-01488, and one
`is marked Exhibit 2041 in IPR2017-01489.
` These are the two declarations that you've
`submitted in these proceedings?
` A I just wanted to make sure my signature is
`on there.
` Yes, they are.
` Q Okay. Is it fair to say that the two
`declarations are substantively identical in terms of
`their content?
` A As far as I remember, yes.
` Q Okay. At the time you signed them, you
`believed them to be true and accurate to the best of
`your knowledge; is that right?
` A Yes, I did.
` Q Okay. Is there anything that you now
`realize is -- was in error or that you want to
`change?
` A No. I -- I -- there's one or two typos,
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`
`
`13 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:15:25
`09:15:29
`09:15:32
`09:15:33
`09:15:35
`09:15:36
`09:15:36
`09:15:40
`09:15:40
`09:15:42
`09:15:44
`09:15:50
`09:15:56
`09:15:57
`09:16:12
`09:16:12
`09:16:14
`09:16:15
`09:16:17
`09:16:20
`09:17:30
`09:17:31
`09:17:33
`09:17:35
`09:17:37
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`14
`
`very minor things, a missing word, a missing comma, a
`missing exponent on the 9. But as far as substance
`are concerned, no.
` Q Okay. Well, as we go through, if there's
`anything you see that you --
` A Sure.
` Q -- need to change in terms of typos --
` A Sure.
` Q -- please let me know.
` Now, at the back of each of your
`declarations, you will see that there is a list of
`the materials that -- well, it's a "Materials
`Considered" list.
` Do you see that?
` A Exhibit B?
` Q Exhibit B. Yes.
` A I see that.
` Q Okay. And did you review and consider each
`of the documents in that "Materials Considered" list
`in each of your declarations?
` A I don't -- I don't remember every single one
`of them, but I recognize most of these, yes.
` Q Okay. And you read and understood all of
`these references before providing your declaration;
`is that right?
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`14 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:17:39
`09:17:44
`09:17:49
`09:17:54
`09:17:56
`09:18:02
`09:18:03
`09:18:16
`09:18:18
`09:18:20
`09:18:24
`09:18:29
`09:18:32
`09:18:34
`09:18:37
`09:18:39
`09:18:42
`09:18:44
`09:18:57
`09:18:58
`09:19:07
`09:19:07
`09:19:09
`09:19:14
`09:19:18
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`15
`
` A I -- to the extent that I was required to --
`that I was required to for my deposition, yes -- for
`my declaration.
` Q Okay. Do you know if there's any documents
`here that you didn't review completely?
` A "Completely" meaning --
` Q Like, read it from start to finish.
` A I think I've -- I've opened most of the
`documents, whether -- and -- and skimmed through
`them. I -- I can't -- there's so many documents
`here, I can't -- I can't recall every single document
`that's in this particular list as to when I reviewed
`it.
` Q Okay. Is it fair to say, though, if it's
`listed here, it's something that you opened,
`considered relevant enough to consider it, and place
`it on your "Materials Considered" list?
` MR. DANFORD: Objection to form.
` THE WITNESS: Most of the -- the things I --
`I recognize, yes.
`BY MR. LASKY:
` Q Is there anything you're aware of that you
`considered that's missing from this list?
` A Whoa.
` Q And I guess I'm asking if you're aware of
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`15 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:19:20
`09:19:21
`09:19:22
`09:19:28
`09:19:32
`09:19:33
`09:19:33
`09:19:37
`09:19:43
`09:19:45
`09:19:46
`09:19:48
`09:19:49
`09:19:53
`09:19:55
`09:19:58
`09:19:59
`09:20:04
`09:20:07
`09:20:08
`09:20:08
`09:20:09
`09:20:12
`09:20:14
`09:20:19
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`16
`
`it.
` A I'm not aware of any. I'd have to go
`through and -- and check, but I'm not aware of -- of
`any. Most of the papers, of course, I recognize
`right away, and --
` Yes.
` Q Okay. Before -- I want to focus on the time
`before you submitted your declarations up to when you
`submitted them.
` How much time did you spend on the case?
` A Before I submitted the declaration?
` Q Right. Up to the date that you submitted
`the declaration. How much time would you have
`submitted on --
` A Many, many hours.
` Q How many -- how many would you --
` A I haven't added them up yet, but it would be
`tens of hours.
` Q Tens of hours?
` A Yeah. Uh-huh.
` Q Less than 100?
` A I couldn't say if it was less than 100 or
`more than 100, but it was a -- a large number of
`hours.
` Q Okay. And did you read the '213 patent in
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`16 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:20:25
`09:20:26
`09:20:28
`09:20:31
`09:20:35
`09:20:37
`09:20:39
`09:20:41
`09:20:42
`09:20:44
`09:20:46
`09:20:48
`09:20:49
`09:20:51
`09:20:56
`09:20:57
`09:20:58
`09:20:58
`09:21:00
`09:21:02
`09:21:03
`09:21:06
`09:21:08
`09:21:11
`09:21:13
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`17
`
`preparation of your declaration?
` A Yes.
` Q Okay. Do you know how much time you spent
`reviewing that patent?
` A Again, it -- it would -- it's hard to
`estimate because I've reviewed it multiple times. So
`I've read --
` It would be a number of hours.
` Q Okay. And have you read it again since
`you've provided your declaration?
` A I've looked through it. Yeah.
` Q And do you consider yourself to be familiar
`with its contents?
` MR. DANFORD: Objection to form.
` THE WITNESS: I'm generally familiar with
`it.
`BY MR. LASKY:
` Q Okay. And did -- did you review the claims
`that are at the end of the '213 patent?
` A Yes, I did.
` Q Okay. And do you consider yourself to
`understand what the claims mean in providing your
`opinions in this case?
` A As far --
` I believe I understand the claims, yes.
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`17 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:21:14
`09:21:19
`09:21:21
`09:21:24
`09:21:56
`09:21:58
`09:22:07
`09:22:14
`09:22:15
`09:22:16
`09:22:16
`09:22:18
`09:22:20
`09:22:23
`09:22:24
`09:22:25
`09:22:27
`09:22:27
`09:22:34
`09:22:36
`09:22:39
`09:22:43
`09:22:46
`09:22:46
`09:22:48
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`18
`
` Q Okay. Other than counsel for Genentech,
`have you had any discussions with anyone in
`connection with this case?
` A No.
` Q I've handed you a copy of what's been marked
`as Pfizer Exhibit 1001 in the 01488 IPR.
` Is this the '213 patent that's at issue in
`this case?
` A Was that a question?
` Q Yeah. Is it -- yeah.
` Just for the record, is this the '213 patent
`that you considered for this case?
` A It says '213 at the top, so I'll take it as
`'213. Yes.
` Q Okay. Do you recognize it, though, as
`the -- as the patent that you have provided opinions
`on in this case?
` A Yes.
` Q Okay. I just want to -- you've -- you've
`provided some opinions that you disagree with
`Dr. Foote and Dr. Riechmann and their opinions
`regarding the '213 patent; right?
` A Correct.
` Q I just want to try to get some points of
`agreement, though. And I want to focus on the date
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`18 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:22:54
`09:23:00
`09:23:03
`09:23:08
`09:23:13
`09:23:15
`09:23:15
`09:23:18
`09:23:22
`09:23:33
`09:23:36
`09:23:41
`09:23:42
`09:23:47
`09:23:47
`09:23:49
`09:23:53
`09:23:58
`09:24:00
`09:24:03
`09:24:05
`09:24:06
`09:24:06
`09:24:13
`09:24:27
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`19
`
`before the invention that's described in the '213
`patent. And I know there's some dispute about that
`date. So I just want to focus on the time before the
`invention was made. Is that okay? I'm going to ask
`you questions about that.
` A Yeah. Sure.
` Q Okay. Now, before that invention date of
`the '213 patent, you would agree that it was known
`that overexpression of the HER2 protein led to a poor
`prognosis in cancer, including breast cancer; right?
` MR. DANFORD: Objection. Outside the scope.
` THE WITNESS: If you're asking if there were
`papers on that protein, the answer would be yes.
`BY MR. LASKY:
` Q Right. You don't dispute, though, that it
`was known that overexpression of HER2 led to a
`particularly poor prognosis in breast cancer prior to
`the '213 patent invention; right?
` MR. DANFORD: Objection. Outside the scope.
` THE WITNESS: I believe that there was some
`correlation. Yes.
`BY MR. LASKY:
` Q And prior to the '213 patent invention, work
`had been done to identify murine antibodies that
`would target the HER2 receptor; is that right?
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`19 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:24:30
`09:24:30
`09:24:33
`09:24:37
`09:24:43
`09:24:46
`09:24:47
`09:24:51
`09:24:58
`09:25:02
`09:25:03
`09:25:06
`09:25:08
`09:25:39
`09:25:41
`09:25:47
`09:25:52
`09:25:54
`09:25:55
`09:25:56
`09:25:59
`09:26:00
`09:26:01
`09:26:04
`09:26:07
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`20
`
` A I believe that is the case. Yes.
` Q And so, for example, in the Hudziak,
`H-u-d-z-i-a-k, reference, the authors described the
`generation of a number of antibodies, mouse
`antibodies, against the HER2 receptor; is that right?
` A That is correct.
` Q And Hudziak and co-authors, prior to the
`'213 patent invention, had tested those mouse
`antibodies for their ability to stem cell
`proliferation; right?
` A Could you show me the patent to -- show me
`the paper to refresh my memory.
` Q Okay. Sorry.
` Dr. Wilson, I've handed you a copy of what's
`been marked as Pfizer Exhibit 1021 in the 01488 IPR,
`and this is the Hudziak reference I was referring to.
` Have you reviewed this for purposes of this
`case?
` A Yes, I have.
` Q Okay. And it's published in March 1989; is
`that right?
` A That is correct.
` Q And that's before the '213 patent invention;
`is that right?
` A Yes.
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`20 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:26:08
`09:26:14
`09:26:21
`09:26:27
`09:26:31
`09:26:34
`09:26:35
`09:26:36
`09:26:42
`09:26:50
`09:26:50
`09:26:53
`09:26:56
`09:27:00
`09:27:08
`09:27:08
`09:27:09
`09:27:13
`09:27:17
`09:27:21
`09:27:25
`09:27:27
`09:27:32
`09:27:32
`09:27:33
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`21
`
` Q Okay. And -- and if you -- if you look at
`the introduction, Hudz- -- in the last paragraph of
`the introduction, the authors note that, to
`facilitate investigation of the normal role of the
`HER2 gene product --
` Oh, I'm sorry.
` A So where are we?
` Q In the introduction to the paper and the
`last paragraph.
` A Okay.
` Q They note that, to facilitate investigation
`of the normal biological role of the HER2 gene
`product, they prepared monoclonal antibodies against
`the extracellular domain of the p185 HER2 protein.
` Do you see that?
` A Yes, I see that.
` Q And then one of those monoclonal antibodies,
`the 4D5, was characterized in more detail and shown
`to inhibit in vitro proliferation of human
`breast canc- -- tumor cells overexpressing HER2 and
`furthermore to increase the sensitivity of these
`cells to the cytotoxic effects of TNF-alpha.
` Do you see that?
` A Yes, I see that.
` Q And then, if you look over to page 11 of the
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`21 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:27:36
`09:27:43
`09:27:52
`09:27:58
`09:28:01
`09:28:03
`09:28:04
`09:28:05
`09:28:10
`09:28:13
`09:28:15
`09:28:15
`09:28:17
`09:28:21
`09:28:25
`09:28:29
`09:28:41
`09:28:46
`09:28:47
`09:28:49
`09:28:55
`09:28:56
`09:28:56
`09:29:05
`09:29:09
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`22
`
`exhibit and table 1 of the reference, you see there
`is a test of certain mono- -- the -- the ability of
`certain monoclonal antibodies to inhibit tumor
`cell -- tumor cell line proliferation by
`anti-HER2 [sic] monoclonal antibodies.
` Do you see that?
` A I do.
` Q And the 4D5 antibody was shown to have
`the -- the greatest effect of relative cell
`proliferation.
` Do you see that?
` A That is correct.
` Q Okay. And -- and so back to my original
`question. Before the '213 patent invention, Hudziak
`and colleagues had shown that the 4D5 antibody was
`able to inhibit cell proliferation through targeting
`the HER2 receptor; is that right?
` MR. DANFORD: Objection to form.
` THE WITNESS: It was shown to inhibit the
`proliferation of the SK-BR-3 breast tumor cells.
`Yes.
`BY MR. LASKY:
` Q And the 4D5 antibody that was being tested
`by Hudziak was a mouse antibody; is that right?
` A Yes.
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`
`
`22 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:29:09
`09:29:12
`09:29:17
`09:29:22
`09:29:25
`09:29:26
`09:29:27
`09:29:30
`09:29:32
`09:29:32
`09:29:35
`09:29:48
`09:29:48
`09:29:53
`09:29:57
`09:29:57
`09:29:59
`09:30:01
`09:30:07
`09:30:15
`09:30:19
`09:30:23
`09:30:24
`09:30:25
`09:30:25
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`23
`
` Q And prior to the '213 patent invention, it
`was known that mouse antibodies had limited value as
`human therapeutics due to the likelihood of
`immunogenicity; is that right?
` MR. DANFORD: Objection to form.
` THE WITNESS: There was a concern that you
`might get a reaction against a mouse antibody if you
`give it to a human. Yes.
`BY MR. LASKY:
` Q Okay. Prior to the '213 patent invention,
`scientists investigated ways to avoid or minimize the
`immunogenetic -- immugenic -- immunogenic potential
`of murine monoclonal antibodies; right?
` MR. DANFORD: Objection to form.
` THE WITNESS: Yes.
`BY MR. LASKY:
` Q And you don't dispute in your declaration
`that, prior to the '213 patent invention, there was a
`motivation to try to develop the 4D5 monoclonal
`antibody as a human therapeutic agent; right?
` MR. DANFORD: Objection to form.
` THE WITNESS: I don't really know if I quite
`understand the question.
`BY MR. LASKY:
` Q Okay.
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`23 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:30:26
`09:30:29
`09:30:31
`09:30:34
`09:30:35
`09:30:36
`09:30:40
`09:30:45
`09:30:46
`09:30:47
`09:30:47
`09:30:48
`09:30:53
`09:31:01
`09:31:04
`09:31:05
`09:31:07
`09:31:07
`09:31:08
`09:31:09
`09:31:12
`09:31:13
`09:31:16
`09:31:20
`09:31:25
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`24
`
` A I understand, but I don't understand the
`intent of the question is really --
` Q Oh, okay. I mean, there's no intent. I'm
`just trying to --
` A No. There's -- there's many -- there's
`many -- many antibodies you could actually have
`looked at. 4D4 -- 4D5 was an antibody that had been
`identified.
` Q Okay.
` A Yep.
` Q And in -- and Hudziak, at least, had shown
`4D5 to be the -- the most effective at
`antiproliferative activity against HER2
`overexpressing breast cancer cells; right?
` MR. DANFORD: Objection to form.
` THE WITNESS: In the study that they did.
`BY MR. LASKY:
` Q Uh-huh.
` A I don't know if that -- if there could have
`been a better antibody, but in the part they looked
`at, yes.
` Q Okay. So my question is: Prior to the '213
`patent invention, you would agree that, based on
`Hudziak's data, there was a motivation to investigate
`the 4D5 antibody as a human therapeutic agent against
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`24 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:31:29
`09:31:33
`09:31:34
`09:31:36
`09:31:38
`09:31:41
`09:31:46
`09:31:46
`09:31:48
`09:31:54
`09:31:57
`09:32:05
`09:32:06
`09:32:07
`09:32:09
`09:32:11
`09:32:13
`09:32:13
`09:32:24
`09:32:32
`09:32:38
`09:32:43
`09:32:46
`09:32:46
`09:32:54
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`25
`
`HER2 overexpressing breast cancer; right?
` MR. DANFORD: Objection. Asked and
`answered.
` THE WITNESS: That antibody was one of many,
`but that is -- Hudziak identified that as a
`potential.
`BY MR. LASKY:
` Q And with respect to that 4D5 antibody,
`though, again, it was known that, as a murine
`antibody, it would be likely to be ineffective as a
`human therapeutic agent due to the immunogenic
`potential; right?
` MR. DANFORD: Objection to form.
` THE WITNESS: One can't tell until one did,
`actually, the experiment, but that would have been a
`concern from -- generally from mouse antibodies.
`BY MR. LASKY:
` Q Okay. Now, prior to the '213 patent
`invention, scientists had investigated ways to reduce
`the immunogenic potential of murine monoclonal
`antibodies, one way being to develop a chimeric
`antibody; right?
` A That is correct.
` Q And the chimeric antibody was made by
`placing the murine variable domain on a human
`
`1 2 3 4 5 6 7 8 9 1
`
`0
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`25 of 362
`
`Celltrion, Inc. 1138
`Celltrion v. Genentech
`IPR2017-01374
`
`
`
`09:32:59
`09:33:00
`09:33:03
`09:33:08
`09:33:16
`09:33:20
`09:33:25
`09:33:28
`09:33:29
`09:33:29
`09:33:32
`09:33:35
`09:33:36
`09:33:41
`09:33:44
`09:33:49
`09:33:50
`09:33:53
`09:33:54
`09:33:54
`09:34:02
`09:34:06
`09:34:11
`09:34:15
`09:34:15
`
`Transcript of Ian A. Wilson, D.Phil.
`Conducted on April 21, 2018
`
`26
`
`constant do